These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35296557)

  • 61. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
    Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
    Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
    BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
    Onozawa M; Akaza H; Hinotsu S; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Tsukamoto T
    Cancer Med; 2018 Oct; 7(10):4893-4902. PubMed ID: 30151999
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
    Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
    Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G; Song G; Huang C; He S; Zhou L
    Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 70. miRNAs and androgen deprivation therapy for prostate cancer.
    Konoshenko MY; Bryzgunova OE; Laktionov PP
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188625. PubMed ID: 34534639
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
    Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
    BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
    Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
    Shiota M; Fujimoto N; Itsumi M; Takeuchi A; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
    Ann Oncol; 2017 Mar; 28(3):569-575. PubMed ID: 27993795
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G; Chen X; Gong U; Chen Y; Li G; Wei F; Jiang A; Niu Y; Shang Z
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
    Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
    J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
    [No Abstract]   [Full Text] [Related]  

  • 78. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.
    Røe K; Mikalsen LT; van der Kogel AJ; Bussink J; Lyng H; Ree AH; Marignol L; Olsen DR
    Radiat Oncol; 2012 May; 7():75. PubMed ID: 22621752
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.